FDA Sets PDUFA Date for Revance DAXI Neuromodulator
One year ago - By Surgical Aesthetics Magazine
The United States Food and Drug Administration has accepted the Biologics License Application for Revance Therapeutics' DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar lines. In a press release issued by Revance, the company noted that, in its correspondence, the FDA stated that no potential filing review issues were identified and indicated in the BLA filing communication letter that it is not currently planning to hold an advisory committee meeting to discuss the application. The FDA set a target Prescription Drug User Fee Act action date of November...
Read more ...
The headlines of Master Doctor
Cosmetic surgeon faces legal action over operation on teenager's labia
A Melbourne cosmetic surgeon faces civil court action over the removal of a 13-year-old girl's labia that allegedly left her disfigured and suffering serious psychological trauma.
How Can Women Benefit From Laser Hair Removal During Summertime?
3 Minute Read: Summertime often means trips to the beach and laying out by the pool. Having to shave before every event or gathering can be time-consuming and inconvenient. We...
Dedicated cGMP Facility for Porous Plastic Components
Porvair Sciences reports investment in a dedicated clean area for manufacturing Vyon® porous plastic components for healthcare, pharmaceutical and life science products.